Status: Divested (December ‘10, June ‘15)
Type of investment: Development Capital
Equity stake: 28.13% (at exit)
Turnover: Eur 92.4 mln (at exit)
Suzho Tianma Tianji Bio-Pharmaceuticals is focused on the production of Active pharmaceutical ingredients (“APIs”) for generic drugs, formulation (lyophilized and small volume injection dosage), and peptides. The company is the largest Chinese API producer of Clindamycin Phosphate, Citicoline Sodium, and Carbetapentane, with good local market share. The company has one plant in Suzhou, China, employing 470 employees at the time of the exit.